false
0001411685
0001411685
2024-05-23
2024-05-23
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 23, 2024
Vistagen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
N 000-54014 20-5093315
evada
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification Number)
343 Allerton Ave.
South San Francisco
,
California
94080
(Address of principal executive offices)
(
650
)
577-3600
(Registrant
'
s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d -2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock VTGN Nasdaq
, par value $0.001 per share Capital Market
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule
12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2)
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying with any new
or revised financial accounting standards provided pursuant to Section 13(a)
of the Exchange Act
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
-------------------------------------------------------------------------------
Item 8.01 Other Events.
On May 23, 2024, Vistagen Therapeutics, Inc. (the "
Company
") announced that it will present posters highlighting fasedienol, the
Company's investigational pherine candidate in Phase 3 development for the
acute treatment of social anxiety disorder, and itruvone, the Company's
investigational pherine candidate in Phase 2 development for the treatment of
major depressive disorder, at the American Society of Clinical Psychopharmacolog
y Conference in Miami Beach, Florida, from May 28 to 31, 2024. A copy of the
press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
.
(d) Exhibits Index
Exhibit No. Description
99.1 Press Release issued by Vistagen Therapeutics, Inc., dated May 23, 2024.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
-------------------------------------------------------------------------------
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Vistagen Therapeutics, Inc.
Date: May 23, 2024 By: /s/ Shawn K. Singh
Shawn K. Singh
Chief Executive Officer
Exhibit 99.1
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology
(ASCP) Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2024
-
Vistagen
(Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering
neuroscience to deliver groundbreaking therapies for individuals affected by
psychiatric and neurological disorders, today announced that it will present
posters highlighting fasedienol, its investigational pherine candidate in
Phase 3 development for the acute treatment of social anxiety disorder (SAD),
and itruvone, its investigational pherine candidate in Phase 2 development for
the treatment of major depressive disorder (MDD), at the American Society of
Clinical Psychopharmacology Conference in Miami Beach, Florida from May 28 to
31, 2024.
Poster Presentation
Date: Wednesday, May 29, 2024, 11:15 a.m. Eastern Time
Title: Fasedienol (PH94B) Nasal Spray for Acute Treatment of Social Anxiety
Disorder (SAD):
Results from the PALISADE-2 Phase 3 Trial
Authors: Michael R. Liebowitz, MD; Ester Salman, MPH; Rita Hanover, PhD;
Brittany Reed, PA; Ross A. Baker, PhD; and Louis Monti, MD, PhD
Poster Number: W96
Poster Presentation
Date: Wednesday, May 29, 2024, 11:15 a.m. Eastern Time
Title: Brain and Peripheral Tissue Distribution of Intranasal Radiolabeled
Itruvone (PH10) in Laboratory Rats
Authors: Jo Cato PhD; Ross A. Baker, PhD; and Louis Monti, MD, PhD
Poster Number: W78
The posters will be available on the
Publications page
of Vistagen's website on Monday, June 3, 2024.
About Fasedienol Nasal Spray
Vistagen's fasedienol (PH94B) is a first-in-class, synthetic rapid-onset
investigational pherine nasal spray in Phase 3 development for the acute
treatment of social anxiety disorder (SAD). Fasedienol's novel neurocircuitry-fo
cused proposed mechanism of action (MOA) is differentiated from the SSRIs and
SNRI currently approved for the treatment of SAD, as well as all benzodiazepines
and other medications prescribed off label for SAD. There is no FDA-approved
acute treatment of SAD. When administered intranasally in microgram-level
doses, fasedienol activates receptors in peripheral nasal chemosensory neurons
that, in turn, activate olfactory system neurocircuitry and limbic amygdala
neurocircuits involved in the pathophysiology of SAD, and potentially other
acute anxiety and mood disorders. Fasedienol is pharmacologically active
without requiring systemic absorption and distribution, or binding to neurons
in the brain. Given fasedienol's rapid-onset MOA and patient-tailored
as-needed administration, it has the potential to become the first
FDA-approved acute treatment for SAD, which is the focus of Vistagen's ongoing
registration-directed PALISADE Phase 3 program. The U.S. FDA has granted Fast
Track designation for the investigation of fasedienol nasal spray for the
acute treatment of SAD.
About Itruvone Nasal Spray
Itruvone (PH10) is a synthetic rapid-onset investigational pherine nasal spray
in Phase 2 development for the treatment of moderate to severe major
depressive disorder (MDD). Itruvone's proposed mechanism of action (MOA) is
fundamentally differentiated from the MOA of all currently approved treatments
for MDD. Administered intranasally at microgram-level doses, itruvone's MOA
involves the regulation of olfactory-to-amygdala neural circuits believed to
increase the activity of the limbic-hypothalamic sympathetic nervous system
and increase the release of catecholamines. Unlike all currently approved
depression therapies, itruvone does not require systemic absorption and
distribution or binding to neurons in the brain to produce antidepressant
effects without the side effects and safety concerns that may be associated
with current antidepressant therapies. The U.S. FDA has granted Fast Track
designation for the development of itruvone as a potential treatment for MDD.
-------------------------------------------------------------------------------
About Vistagen
Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience
to deliver groundbreaking therapies for individuals affected by psychiatric
and neurological disorders. Five of Vistagen's clinical-stage neuroscience
pipeline candidates belong to a new class of drugs known as pherines, which
are investigational neuroactive nasal sprays with innovative proposed
mechanisms of action that activate chemosensory neurons in the nasal passages
to impact fundamental neural circuitry in the brain without the need for
systemic absorption or binding to receptors in the brain. Vistagen's sixth
investigational candidate is an oral prodrug with potential to modulate NMDA
receptor activity. At Vistagen, we are passionate about delivering
differentiated treatments that set new standards of care for people living
with anxiety, depression, and other neurological disorders. Connect at
www.Vistagen.com
.
Forward-looking Statements
This press release contains certain forward-looking statements within the
meaning of the federal securities laws. These forward-looking statements
involve known and unknown risks that are difficult to predict and include all
matters that are not historical facts. In some cases, you can identify
forward-looking statements by the use of words such as
"
may,
"
"
could,
"
"
expect,
"
"
project,
"
"
outlook,
"
"
strategy,
"
"
intend,
"
"
plan,
"
"
seek,
"
"
anticipate,
"
"
believe,
"
"
estimate,
"
"
predict,
"
"
potential,
"
"
strive,
"
"
goal,
"
"
continue,
"
"
likely,
"
"
will,
"
"
would
"
and variations of these terms and similar expressions, or the negative of
these terms or similar expressions. Such forward-looking statements are
necessarily based upon estimates and assumptions that, while considered
reasonable by Vistagen (the Company) and its management, are inherently
uncertain. As with all pharmaceutical products, there are substantial risks
and uncertainties in the process of development and commercialization and
actual results or developments may differ materially from those projected or
implied in these forward-looking statements. Among other things, there can be
no guarantee that any of the Company
'
s drug candidates will successfully complete ongoing or future clinical
trials, receive regulatory approval or be commercially successful. These risks
and others are more fully discussed in the section entitled
"
Risk Factors
"
in the Company
'
s most recent Annual Report on Form 10-K for the fiscal year ended March 31,
2023, and in the Company
'
s Quarterly Report on Form 10-Q for the period ended December 31, 2023, as
well as discussions of potential risks, uncertainties, and other important
factors in our other filings with the U.S. Securities and Exchange Commission
(SEC). The Company
'
s SEC filings are available on the SEC
'
s website at www.sec.gov. You should not place undue reliance on these
forward-looking statements, which apply only as of the date of this press
release and should not be relied upon as representing the Company
'
s views as of any subsequent date. The Company explicitly disclaims any
obligation to update any forward-looking statements other than as may be
required by law. If the Company does update one or more forward-looking
statements, no inference should be made that the Company will make additional
updates with respect to those or other forward-looking statements.
Investors:
Mark McPartland
Vistagen Therapeutics
markmcp@vistagen.com
Media:
Caren Scannell
Vistagen Therapeutics
cscannell@vistagen.com
{graphic omitted}
{graphic omitted}
{graphic omitted}